Browsing Clinical Studies by author "Popat, Sanjay"
Now showing items 41-50 of 50
-
RELAY, Ramucirumab Plus Erlotinib (RAM+ERL) in Untreated Metastatic EGFR-Mutant NSCLC (EGFR+ NSCLC): Association Between TP53 Status and Clinical Outcome.
Nishio, M; Paz-Ares, L; Reck, M; Nakagawa, K; Garon, EB; et al. (Elsevier BV, 2023-03-21)BACKGROUND: Ramucirumab plus erlotinib (RAM+ERL) demonstrated superior progression-free survival (PFS) in RELAY, a randomised Phase III trial in patients with untreated, metastatic, EGFR-mutated, non-small-cell lung cancer ... -
Sequential afatinib and osimertinib in patients with EGFR mutation-positive NSCLC and acquired T790M: A global non-interventional study (UpSwinG).
Popat, S; Jung, HA; Lee, SY; Hochmair, MJ; Lee, SH; et al. (2021-09-21)Background Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are standard of care for EGFR mutation-positive non-small cell lung cancer (NSCLC). However, optimal sequence of treatment has yet to be ... -
Severe Immune Checkpoint Inhibitor Hepatitis in KRAS G12C-Mutant NSCLC Potentially Triggered by Sotorasib: Case Report.
Begum, P; Goldin, RD; Possamai, LA; Popat, S (ELSEVIER, 2021-09-01)Sotorasib is a first-in-class small molecule that irreversibly inhibits KRAS G12C, locking it in an inactive state, inhibiting oncogenic signaling, and inducing a proinflammatory microenvironment. Here, we report the first ... -
A Subset of Non-Small Cell Lung Cancer Patients Treated with Pemetrexed Show 18F-Fluorothymidine "Flare" on Positron Emission Tomography.
Aravind, P; Popat, S; Barwick, TD; Soneji, N; Lythgoe, M; et al. (MDPI, 2023-07-22)UNLABELLED: Thymidylate synthase (TS) remains a major target for cancer therapy. TS inhibition elicits increases in DNA salvage pathway activity, detected as a transient compensatory "flare" in 3'-deoxy-3'-[18F]fluorothymidine ... -
Symptom and Quality of Life Improvement in LUX-Lung 8, an Open-Label Phase III Study of Second-Line Afatinib Versus Erlotinib in Patients With Advanced Squamous Cell Carcinoma of the Lung After First-Line Platinum-Based Chemotherapy.
Felip, E; Hirsh, V; Popat, S; Cobo, M; Fülöp, A; et al. (2018-01)Introduction In the phase III LUX-Lung 8 trial, afatinib significantly improved progression-free survival (PFS) and overall survival (OS) versus erlotinib in patients with squamous cell carcinoma (SCC) of the lung progressing ... -
A tailored approach to horizon scanning for cancer medicines.
Soon, JA; To, YH; Alexander, M; Trapani, K; Ascierto, PA; et al. (ELSEVIER SCI LTD, 2023-12-01)BACKGROUND: Horizon scanning (HS) is the systematic identification of emerging therapies to inform policy and decision-makers. We developed an agile and tailored HS methodology that combined multi-criteria decision analysis ... -
The National Lung Matrix Trial: translating the biology of stratification in advanced non-small-cell lung cancer.
Middleton, G; Crack, LR; Popat, S; Swanton, C; Hollingsworth, SJ; et al. (2015-12)Background The management of NSCLC has been transformed by stratified medicine. The National Lung Matrix Trial (NLMT) is a UK-wide study exploring the activity of rationally selected biomarker/targeted therapy combinatio ... -
Transportability of Overall Survival Estimates From US to Canadian Patients With Advanced Non-Small Cell Lung Cancer With Implications for Regulatory and Health Technology Assessment.
Ramagopalan, SV; Popat, S; Gupta, A; Boyne, DJ; Lockhart, A; et al. (AMER MEDICAL ASSOC, 2022-11-01)IMPORTANCE: The external validity of survival outcomes derived from clinical practice data from US patients with advanced non-small cell lung cancer (NSCLC) is not known and is of potential importance because it may be ... -
Tyrosine Kinase Inhibitor Activity in Patients with NSCLC Harboring Uncommon EGFR Mutations: A Retrospective International Cohort Study (UpSwinG).
Popat, S; Hsia, T-C; Hung, J-Y; Jung, HA; Shih, J-Y; et al.<h4>Background</h4>Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR TKIs) are standard of care for patients with EGFR mutation-positive non-small-cell lung cancer (NSCLC) with common mutations (Del19 or ... -
Y disruption, autosomal hypomethylation and poor male lung cancer survival.
Willis-Owen, SAG; Domingo-Sabugo, C; Starren, E; Liang, L; Freidin, MB; et al. (2021-06-14)Lung cancer is the most frequent cause of cancer death worldwide. It affects more men than women, and men generally have worse survival outcomes. We compared gene co-expression networks in affected and unaffected lung ...